標題：本妥昔單抗 ，Brentuximab，CAS:914088-09-8， AntibodySystem Laboratories

貨號：DHD80901

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75131.html

別名：SGN-35, cAC10-Val-Cit-MMAE, CAS: 914088-09-8

簡介：

Brentuximab 是靶向 CD30 的嵌合抗體。Brentuximab 可用于新興靶向療法的研究。

貨號：DHD80901

產(chǎn)品品牌：Antibodysystem

通用名：Brentuximab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內毒素：Please contact with the lab for this information.

別名：SGN-35, cAC10-Val-Cit-MMAE

靶點;物種：Human CD30/TNFRSF8

種類：Chimeric

受體鑒定：IgG1-kappa

CAS: 914088-09-8

存儲條件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻：

Brentuximab Vedotin. PMID: 31644109
Brentuximab vedotin in T-cell lymphoma. PMID: 30526166
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. PMID: 33721562
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. PMID: 36322844
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. PMID: 25796459
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma. PMID: 28190142
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. PMID: 34507350
Brentuximab vedotin. PMID: 22212672
Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. PMID: 33684925
Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. PMID: 32016790
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. PMID: 24652992
Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma. PMID: 32677451
Brentuximab vedotin: clinical updates and practical guidance. PMID: 29333400
Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. PMID: 36260800
Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma. PMID: 25848209
Brentuximab vedotin improves outcomes. PMID: 36418475
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. PMID: 22614995
Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. Reply. PMID: 36260801
Brentuximab vedotin for the treatment of Hodgkin's lymphoma. PMID: 25967932
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. PMID: 25772232
Brentuximab Vedotin Infusion Reaction Management: A Case Study. PMID: 30310723
Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. PMID: 23515511
Brentuximab vedotin in Hodgkin's lymphoma. PMID: 22937794
Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review. PMID: 35481332
Brentuximab Vedotin in CD30+ Lymphomas. PMID: 24392301
Brentuximab-related apoptotic colopathy. PMID: 32345520
Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition? PMID: 33409966
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. PMID: 36403579
Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. PMID: 30122950
Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study. PMID: 35249444
Brentuximab vedotin: frontline help in ALCL. PMID: 34196680
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma. PMID: 31849558
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. PMID: 22454421
A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. PMID: 27139729
Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma. PMID: 24287065
Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. PMID: 22127011
Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma. PMID: 23991923
Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management. PMID: 28805086
Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma. PMID: 22536568
Case Report: Brentuximab Vedotin Associated Acute Pancreatitis in a Pediatric Hodgkin Lymphoma Patient: Case Report and Literature Review. PMID: 36032658
Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma. PMID: 25892213
Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis. PMID: 27096887
Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies. PMID: 25945039
Brentuximab vedotin for the treatment of CD30+ lymphomas. PMID: 21463188
Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. PMID: 22395252
Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. PMID: 23006951
Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. PMID: 26195435
Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome. PMID: 33377934
[Brentuximab vedotin: new treatment for CD30+ lymphomas]. PMID: 23831822
Brentuximab vedotin for treatment of systemic T-cell lymphoma. PMID: 25200691
Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate. PMID: 23307550
Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy. PMID: 25642958
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. PMID: 27279289
Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma? PMID: 22669711
Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells. PMID: 21121873
Brentuximab vedotin: targeting CD30 as standard in CTCL. PMID: 29552279
An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma. PMID: 31432732
Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. PMID: 23494187
Novel Therapies in the Treatment of Hodgkin Lymphoma. PMID: 33755826
Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy. PMID: 30504312
Brentuximab-induced hand-foot syndrome in a patient with cutaneous T-cell lymphoma. PMID: 35242962
Efficacy of antibody-drug conjugate brentuximab vedotin in treating Hodgkin's lymphoma. PMID: 29999431
Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies. PMID: 27592544
Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma. PMID: 26841013
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. PMID: 34889401
Brentuximab Vedotin May Cut Radiation Use in Pediatric Hodgkin Lymphoma. PMID: 33893152
FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town? PMID: 31166030
Brentuximab-Induced Colitis in a Non-Stem-Cell Transplant Patient. PMID: 36713279
Brentuximab-induced splinter nail haemorrhages in a patient with Sézary syndrome: A case report. PMID: 35088431
Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma. PMID: 34879742
Brentuximab-Induced Sensorimotor Polyneuropathy With Acquired Demyelinating Features Resembling Chronic Inflammatory Demyelinating Polyneuropathy. PMID: 35188920
Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T-cell lymphoma: A FIL phase 2 study. PMID: 35023190
[Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma]. PMID: 33308986
Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? PMID: 34965703
Brentuximab vedotin in the treatment of CD30+ PTCL. PMID: 31697814
Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma. PMID: 35107876
Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma. PMID: 31392578